Johnson & Johnson (JNJ) Holder Yacktman Asset Management LP Has Lowered Stake as Share Price Rose; As Boston Scientific (BSX) Market Valuation Rose, Evercore Trust Company Lowered Its Holding

December 7, 2017 - By Maria Brooks

Evercore Trust Company decreased its stake in Boston Scientific Corp (BSX) by 1.58% based on its latest 2017Q2 regulatory filing with the SEC. Evercore Trust Company sold 186,488 shares as the company’s stock rose 4.02% with the market. The institutional investor held 11.62M shares of the medical and dental instruments company at the end of 2017Q2, valued at $322.08 million, down from 11.81 million at the end of the previous reported quarter. Evercore Trust Company who had been investing in Boston Scientific Corp for a number of months, seems to be less bullish one the $34.66 billion market cap company. The stock increased 1.20% or $0.3 during the last trading session, reaching $25.24. About 12.02 million shares traded or 72.00% up from the average. Boston Scientific Corporation (NYSE:BSX) has risen 19.12% since December 7, 2016 and is uptrending. It has outperformed by 2.42% the S&P500.

Donald Yacktman decreased its stake in Johnson & Johnson (JNJ) by 4.12% based on its latest 2017Q2 regulatory filing with the SEC. Yacktman Asset Management Lp sold 243,908 shares as the company’s stock rose 6.85% with the market. The hedge fund run by Donald Yacktman held 5.68M shares of the major pharmaceuticals company at the end of 2017Q2, valued at $750.79 million, down from 5.92M at the end of the previous reported quarter. Yacktman Asset Management Lp who had been investing in Johnson & Johnson for a number of months, seems to be less bullish one the $378.96 billion market cap company. The stock increased 1.00% or $1.39 during the last trading session, reaching $141.06. About 5.59M shares traded or 4.28% up from the average. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since December 7, 2016 and is uptrending. It has underperformed by 4.16% the S&P500.




More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Seekingalpha.com which released: “Johnson & Johnson: Buy The Pause” on November 29, 2017, also Fiercebiotech.com with their article: “Johnson & Johnson’s JLABS looks east as it lands in Shanghai” published on December 05, 2017, Fool.com published: “Better Buy: Pfizer Inc. vs. Johnson & Johnson” on December 01, 2017. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Forbes.com and their article: “The Outlook For Johnson & Johnson’s Immunology Drug Business” published on December 05, 2017 as well as Fool.com‘s news article titled: “3 Dividend Stocks That Pay You More Than Johnson & Johnson Does” with publication date: December 04, 2017.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on January, 23. They expect $1.72 earnings per share, up 8.86% or $0.14 from last year’s $1.58 per share. JNJ’s profit will be $4.62B for 20.50 P/E if the $1.72 EPS becomes a reality. After $1.90 actual earnings per share reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -9.47% negative EPS growth.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 13 have Buy rating, 5 Sell and 5 Hold. Therefore 57% are positive. Johnson & Johnson had 83 analyst reports since August 7, 2015 according to SRatingsIntel. Vetr downgraded it to “Strong-Buy” rating and $106.73 target in Monday, August 31 report. As per Friday, October 6, the company rating was maintained by Cowen & Co. As per Tuesday, July 18, the company rating was maintained by Piper Jaffray. Barclays Capital maintained the stock with “Equal-Weight” rating in Wednesday, October 18 report. The company was maintained on Monday, October 23 by Citigroup. As per Wednesday, October 11, the company rating was upgraded by Jefferies. On Friday, July 14 the stock rating was maintained by Jefferies with “Hold”. The company was maintained on Tuesday, March 15 by Jefferies. The firm has “Neutral” rating by Piper Jaffray given on Monday, October 5. As per Wednesday, August 2, the company rating was maintained by BTIG Research.

Investors sentiment decreased to 0.83 in Q2 2017. Its down 0.03, from 0.86 in 2017Q1. It fall, as 50 investors sold JNJ shares while 878 reduced holdings. 105 funds opened positions while 667 raised stakes. 1.73 billion shares or 0.03% less from 1.73 billion shares in 2017Q1 were reported. Qci Asset Mgmt New York owns 141,270 shares for 2.25% of their portfolio. Holderness Investments invested in 27,321 shares or 1.92% of the stock. Moreover, Gould Asset Mngmt Limited Liability Company Ca has 0.13% invested in Johnson & Johnson (NYSE:JNJ) for 2,075 shares. C Worldwide Grp Inc Hldg A S owns 0.57% invested in Johnson & Johnson (NYSE:JNJ) for 286,147 shares. Armstrong Henry H Assocs Inc has 12.56% invested in Johnson & Johnson (NYSE:JNJ). Rowland Invest Counsel Adv stated it has 0% of its portfolio in Johnson & Johnson (NYSE:JNJ). Wespac Advisors Limited Liability Company reported 6,619 shares. Moreover, Saturna has 2.69% invested in Johnson & Johnson (NYSE:JNJ). Rench Wealth Management Inc, a Texas-based fund reported 36,180 shares. Stonebridge Limited Co reported 1.8% in Johnson & Johnson (NYSE:JNJ). Keystone Planning owns 32,969 shares for 2.64% of their portfolio. Burt Wealth invested 1.25% of its portfolio in Johnson & Johnson (NYSE:JNJ). Anchor Cap Advsr Ltd has 0.96% invested in Johnson & Johnson (NYSE:JNJ). Cap World reported 26.51M shares. Diligent Limited Liability accumulated 6,670 shares or 0.63% of the stock.

Yacktman Asset Management Lp, which manages about $30.82 billion and $10.28B US Long portfolio, upped its stake in Twentyfirst Cen Fox B (NASDAQ:FOX) by 709,760 shares to 27.29 million shares, valued at $760.69 million in 2017Q2, according to the filing.

Among 28 analysts covering Boston Scientific Corporation (NYSE:BSX), 23 have Buy rating, 0 Sell and 5 Hold. Therefore 82% are positive. Boston Scientific Corporation had 78 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, October 26 by Stifel Nicolaus. Needham maintained the stock with “Buy” rating in Thursday, October 26 report. The stock of Boston Scientific Corporation (NYSE:BSX) has “Buy” rating given on Wednesday, November 29 by Canaccord Genuity. Jefferies maintained the stock with “Hold” rating in Tuesday, September 5 report. As per Thursday, April 28, the company rating was maintained by Stifel Nicolaus. The stock has “Buy” rating by BMO Capital Markets on Monday, June 19. On Thursday, November 30 the stock rating was upgraded by BTIG Research to “Buy”. Benchmark maintained Boston Scientific Corporation (NYSE:BSX) on Thursday, July 23 with “Buy” rating. The firm has “Buy” rating by Needham given on Wednesday, June 28. Needham maintained Boston Scientific Corporation (NYSE:BSX) rating on Thursday, June 22. Needham has “Buy” rating and $32 target.

Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on February, 1. They expect $0.34 EPS, up 13.33% or $0.04 from last year’s $0.3 per share. BSX’s profit will be $466.89 million for 18.56 P/E if the $0.34 EPS becomes a reality. After $0.31 actual EPS reported by Boston Scientific Corporation for the previous quarter, Wall Street now forecasts 9.68% EPS growth.

More important recent Boston Scientific Corporation (NYSE:BSX) news were published by: Nasdaq.com which released: “Associated Banc-corp Buys Boston Scientific Corp, Analog Devices Inc …” on November 13, 2017, also Prnewswire.com published article titled: “Boston Scientific To Participate In Piper Jaffray 29th Annual Healthcare …”, Prnewswire.com published: “Boston Scientific To Participate In Stifel 2017 Healthcare Conference” on November 08, 2017. More interesting news about Boston Scientific Corporation (NYSE:BSX) was released by: Prnewswire.com and their article: “Boston Scientific Announces Update on LOTUS Edgeâ„¢ Aortic Valve System” with publication date: November 29, 2017.

Investors sentiment increased to 1.03 in Q2 2017. Its up 0.14, from 0.89 in 2017Q1. It increased, as 41 investors sold BSX shares while 173 reduced holdings. 56 funds opened positions while 165 raised stakes. 1.22 billion shares or 0.64% less from 1.23 billion shares in 2017Q1 were reported. Legacy Private Com has invested 0.03% in Boston Scientific Corporation (NYSE:BSX). 7,298 are owned by Jnba Advisors. Dynamic Management Limited stated it has 0.3% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Veritable Limited Partnership invested in 0.04% or 56,263 shares. Guardian Life Company Of America has invested 0.01% in Boston Scientific Corporation (NYSE:BSX). Whittier Tru Of Nevada Inc has invested 0% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Shell Asset owns 161,181 shares. Hartford Investment reported 0.16% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Parametrica Mngmt Limited holds 0.21% or 7,887 shares in its portfolio. 31,786 were reported by Nottingham. Advent Cap Mngmt De accumulated 23,000 shares or 0.01% of the stock. Sterling Llc accumulated 306,649 shares or 0.08% of the stock. Shine Inv Advisory Service holds 0.02% of its portfolio in Boston Scientific Corporation (NYSE:BSX) for 1,322 shares. Fernwood Investment Management Ltd Liability invested in 0.88% or 43,774 shares. Commonwealth Of Pennsylvania School Empls Retrmt System reported 0.04% in Boston Scientific Corporation (NYSE:BSX).

Evercore Trust Company, which manages about $32.80 billion US Long portfolio, upped its stake in Goodyear Tire & Rubr Co (NASDAQ:GT) by 70,480 shares to 3.25M shares, valued at $113.74 million in 2017Q2, according to the filing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: